secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056935
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences Q1 net loss $18.2M; cash $382.5M; TYRA-300 on track for 2H24 milestones
--------------------------------------------------------------------------------

- Net loss of $18.2M in Q1 2024 vs $11.9M in Q1 2023; R&D expenses $17.2M.
- Cash, equivalents, and marketable securities of $382.5M as of March 31, 2024; funding through at least 2026.
- Closed $200M private placement in Feb 2024.
- TYRA-300 on track for ACH IND submission and initial SURF301 results in 2H24.
- Appointed Susan Moran, M.D. and S. Michael Rothenberg, M.D., Ph.D. to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000095017024056935/0000950170-24-056935-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000095017024056935/tyra-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056935

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer